Mutual Advisors LLC Sells 287 Shares of Amgen Inc. (NASDAQ:AMGN)

by · The Cerbat Gem

Mutual Advisors LLC decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,047 shares of the medical research company’s stock after selling 287 shares during the period. Mutual Advisors LLC’s holdings in Amgen were worth $4,688,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of AMGN. Beck Mack & Oliver LLC grew its holdings in shares of Amgen by 0.7% during the 4th quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company’s stock worth $1,205,000 after acquiring an additional 34 shares during the period. Continuum Advisory LLC raised its holdings in Amgen by 0.7% in the fourth quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company’s stock worth $1,343,000 after purchasing an additional 35 shares in the last quarter. Octavia Wealth Advisors LLC lifted its position in Amgen by 1.5% during the first quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company’s stock valued at $759,000 after buying an additional 35 shares during the period. Trillium Asset Management LLC boosted its holdings in shares of Amgen by 4.2% during the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock valued at $237,000 after buying an additional 37 shares in the last quarter. Finally, Affinity Capital Advisors LLC boosted its holdings in shares of Amgen by 4.5% during the 1st quarter. Affinity Capital Advisors LLC now owns 861 shares of the medical research company’s stock valued at $246,000 after buying an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.76% of the stock is owned by insiders.

Amgen Stock Performance

Shares of AMGN stock opened at $298.25 on Friday. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. The company has a 50 day moving average price of $282.12 and a 200-day moving average price of $286.57. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market capitalization of $160.37 billion, a PE ratio of 27.21, a P/E/G ratio of 2.68 and a beta of 0.49.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.96 EPS. As a group, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AMGN shares. Erste Group Bank cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $305.00 target price on shares of Amgen in a report on Tuesday, June 24th. Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. Guggenheim assumed coverage on Amgen in a research report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price objective for the company. Finally, UBS Group reiterated a “neutral” rating and set a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $307.82.

Read Our Latest Analysis on AMGN

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).